VERTEX PHARMACEUTICALS INC / MA (VRTX)

The company is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. Its core strategy is to discover, develop and commercialize innovative medicines by focusing on validated targets that address causal human biology, advancing multiple compounds from each program into early clinical trials, and following first-in-class therapies with potential best-in-class candidates. It also plans to add product candidates through internal research and through business development transactions that give it access to emerging technologies, products and candidates.

Approved medicines cover cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT) and acute pain. The CF portfolio consists of CFTR modulators: ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. ALYFTREK is the most recently approved triple combination and is dosed once daily. CASGEVY is an ex-vivo, non-viral CRISPR/Cas9 gene-editing therapy for severe SCD and TDT, approved in the U.S. and in multiple other geographies. JOURNAVX (suzetrigine) is an oral, non-opioid NaV1.8 pain signal inhibitor that the FDA approved in January 2025 for moderate-to-severe acute pain in adults. Five programs are in pivotal development: - Povetacicept, a dual BAFF/APRIL inhibitor, for IgA nephropathy. A rolling BLA submission began in the fourth quarter of 2025, with completion expected in the first half of 2026. - Povetacicept for primary membranous nephropathy, in a Phase 2/3 trial. - Inaxaplin, an APOL1 inhibitor, for APOL1-mediated kidney disease, in a Phase 2/3 trial. - Suzetrigine for diabetic peripheral neuropathy, in two Phase 3 trials. - Zimislecel, a stem-cell derived islet cell therapy, for type 1 diabetes. Completion of dosing in its Phase 1/2/3 trial is temporarily postponed pending an internal manufacturing analysis. The wider pipeline also includes programs in autosomal dominant polycystic kidney disease and myotonic dystrophy type 1.

The company estimates about 112,000 people with CF in its target markets. Its CF medicines are used by nearly three quarters of the roughly 97,000 people with CF in the U.S., Europe, Australia and Canada, and are reimbursed or accessible in more than 60 countries across six continents. For CASGEVY, it estimates about 60,000 people with severe SCD or TDT are or could become eligible in the geographies where it is approved. CASGEVY is broadly reimbursed by U.S. third-party payors, and agreements with national and regional payors cover more than 275 million lives. Patients outside the U.S. have access in Austria, Denmark, the U.K., Italy, Luxembourg, Bahrain, Saudi Arabia, the UAE and Kuwait. In 2025 about 300 people initiated CASGEVY treatment and 64 received infusions. JOURNAVX targets the U.S. acute pain market, where over 80 million people are prescribed a pain medicine each year.

CASGEVY is delivered through a network of authorized treatment centers, where patients' stem cells are collected and later infused. The collected cells are sent to a manufacturing facility for gene editing and then returned to the treatment center. The text does not identify suppliers, competitors or headquarters.